Abolfazl Akbari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Abolfazl Akbari has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Amir Baniasad
Lung Disease Research Center Mashhad University of Medical Sciences Mashhad Iran
2 shared publications - Hanieh Raji
Air Pollution and Respiratory Diseases Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
2 shared publications - Hossein Mohaddes Ardabili
Psychiatry and Behavioral Sciences Research Center, Ibn-e-Sina Hospital, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
2 shared publications - Mahnaz Amini
Division of Sleep Medicine, Psychiatry and Behavioral Sciences Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
2 shared publications - Sina Samieirad
Department of Otolaryngology–Head and Neck Surgery, Sinus and Surgical Endoscopic Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
2 shared publications Abdulmalik Zuhair Arab
PG Researcher, Division of Systems Medicine, School of Medicine, University of Dundee, UK
1 shared publication
Latest Publications
- Open Access
- 25 August 2026
- Published by Wiley in Clinical and Experimental Dental Research
- Vol. 12 (4) , e70439
Efficacy of Ozonated Gels and Oils As Adjunctive or Monotherapy in Periodontitis: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
Objectives: This study aimed to evaluate the available clinical evidence on the use of ozonated gels and oils in the management of periodontitis. Material and Methods: Embase, SCOPUS, Web of Science, PubMed, and Google Scholar were searched up to May 13, 2025. Original peer‐reviewed randomized controlled trials (RCTs) in English that investigated patients with periodontitis were included. Study characteristics, methods of ozone application, conclusions, and reported complications were extracted. Pooled mean differences of clinical indices were compared between the ozone therapy groups (adjunctive or monotherapy) and control groups (placebo or CHX). Primary outcomes included clinical indices such as probing pocket depth (PPD), plaque index (PI), and gingival index (GI), whereas secondary outcomes comprised clinical attachment level (CAL), clinical attachment loss (CAtL), bleeding on probing (BoP), and sulcus bleeding index (SBI). Results: Of the 962 records, 19 clinical studies were included in the qualitative synthesis and 18 RCTs in the quantitative synthesis. For periodontitis, ozonated compounds significantly reduced PPD when used as an adjunct to subgingival instrumentation (MD = −0.780; p < 0.0001) and reduced clinical attachment loss (CAL) (MD = −0.457; p = 0.001) compared with subgingival instrumentation alone. No statistically significant differences were observed in PI or GI outcomes with ozonated compounds as an adjunct to subgingival instrumentation compared with subgingival instrumentation alone, although sensitivity analyses indicated some instability in the results. Follow‐up periods ranged from 4 to 12 weeks across outcomes (8–12 weeks for GI), with most studies reporting 12‐week follow‐up. No consistent differences were found between ozone and CHX in terms of PPD, CAL, PI or BoP. No adverse effects were reported in the studies. Conclusions: Ozonated gels and oils were associated with favorable periodontal outcomes, particularly when used as adjuncts to subgingival instrumentation, and no major adverse effects were reported. However, the evidence is limited by short‐term follow‐up and methodological heterogeneity.
- 25 August 2026
- Published by Wiley in Clinical and Experimental Dental Research
- Vol. 12 (4) , e70439
Open AccessEfficacy of Ozonated Gels and Oils As Adjunctive or Monotherapy in Periodontitis: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
Objectives: This study aimed to evaluate the available clinical evidence on the use of ozonated gels and oils in the management of periodontitis. Material and Methods: Embase, SCOPUS, Web of Science, PubMed, and Google Scholar were searched up to May 13, 2025. Original peer‐reviewed randomized controlled trials (RCTs) in English that investigated patients with periodontitis were included. Study characteristics, methods of ozone application, conclusions, and reported complications were extracted. Pooled mean differences of clinical indices were compared between the ozone therapy groups (adjunctive or monotherapy) and control groups (placebo or CHX). Primary outcomes included clinical indices such as probing pocket depth (PPD), plaque index (PI), and gingival index (GI), whereas secondary outcomes comprised clinical attachment level (CAL), clinical attachment loss (CAtL), bleeding on probing (BoP), and sulcus bleeding index (SBI). Results: Of the 962 records, 19 clinical studies were included in the qualitative synthesis and 18 RCTs in the quantitative synthesis. For periodontitis, ozonated compounds significantly reduced PPD when used as an adjunct to subgingival instrumentation (MD = −0.780; p < 0.0001) and reduced clinical attachment loss (CAL) (MD = −0.457; p = 0.001) compared with subgingival instrumentation alone. No statistically significant differences were observed in PI or GI outcomes with ozonated compounds as an adjunct to subgingival instrumentation compared with subgingival instrumentation alone, although sensitivity analyses indicated some instability in the results. Follow‐up periods ranged from 4 to 12 weeks across outcomes (8–12 weeks for GI), with most studies reporting 12‐week follow‐up. No consistent differences were found between ozone and CHX in terms of PPD, CAL, PI or BoP. No adverse effects were reported in the studies. Conclusions: Ozonated gels and oils were associated with favorable periodontal outcomes, particularly when used as adjuncts to subgingival instrumentation, and no major adverse effects were reported. However, the evidence is limited by short‐term follow‐up and methodological heterogeneity.
- 26 November 2025
- Published by Springer Nature in Sleep and Breathing
- Vol. 29 (6) , 367
Prevalence and characteristics of pulmonary hypertension in obstructive sleep apnea: a systematic review and meta-analysis
Introduction Pulmonary hypertension (PH) is a serious cardiovascular complication that can be associated with obstructive sleep apnea (OSA). We aimed to assess the prevalence and characteristics of PH in OSA patients. Method On May 13, 2025, a comprehensive literature search was performed to identify studies reporting the prevalence of PH in patients with OSA, or studies that compared OSA patients with and without PH. Data were pooled and subgroup-analyses, sensitivity-analyses and meta-regressions were performed based on apnea-hypopnea-index (AHI) thresholds, PH diagnostic methods, and study characteristics. Results Of 4,852 records, 53 included in the systematic-review and 46 in the quantitative-analysis. Across them, 1,190 OSA patients had PH (55.5%male) and 2,967 did not (64.5%male). The pooled prevalence of PH among OSA patients using AHI ≥ 5 criteria was 29.3% (95%CI[19.4–41.8], I²=94%). Sensitivity-analyses showed similar prevalence estimates when limited to studies using right-heart-catheterization (RHC)(29.6%) or those excluding small sample-sizes (< 50participants:30.9%) or retrospective designs (30.3%). Prevalence increased to 35.5% in studies using AHI ≥ 10 as the diagnostic-threshold. However, no significant difference in PH prevalence was found between mild-to-moderate and severe OSA (OR = 0.976[0.658–1.448], I²=47%). OSA patients with PH had significantly higher body-mass-index (BMI) (mean-difference (MD) = 3.432,P < 0.001), AHI (MD = 12.6,P < 0.001), ODI (standard-mean-difference (SMD) = 0.497), and T < 90% (SMD = 0.641), and lower meanSpO₂ (SMD = − 0.885) compared to those without PH. Age and sex were not different. Conclusions PH is relatively common among patients with OSA, with a pooled prevalence of approximately 29–31%. While OSA severity markers such as AHI and ODI were higher in PH patients, no consistent severity-dependent association with PH prevalence was observed.
- 26 November 2025
- Published by Springer Nature in Sleep and Breathing
- Vol. 29 (6) , 367
Prevalence and characteristics of pulmonary hypertension in obstructive sleep apnea: a systematic review and meta-analysis
Introduction Pulmonary hypertension (PH) is a serious cardiovascular complication that can be associated with obstructive sleep apnea (OSA). We aimed to assess the prevalence and characteristics of PH in OSA patients. Method On May 13, 2025, a comprehensive literature search was performed to identify studies reporting the prevalence of PH in patients with OSA, or studies that compared OSA patients with and without PH. Data were pooled and subgroup-analyses, sensitivity-analyses and meta-regressions were performed based on apnea-hypopnea-index (AHI) thresholds, PH diagnostic methods, and study characteristics. Results Of 4,852 records, 53 included in the systematic-review and 46 in the quantitative-analysis. Across them, 1,190 OSA patients had PH (55.5%male) and 2,967 did not (64.5%male). The pooled prevalence of PH among OSA patients using AHI ≥ 5 criteria was 29.3% (95%CI[19.4–41.8], I²=94%). Sensitivity-analyses showed similar prevalence estimates when limited to studies using right-heart-catheterization (RHC)(29.6%) or those excluding small sample-sizes (< 50participants:30.9%) or retrospective designs (30.3%). Prevalence increased to 35.5% in studies using AHI ≥ 10 as the diagnostic-threshold. However, no significant difference in PH prevalence was found between mild-to-moderate and severe OSA (OR = 0.976[0.658–1.448], I²=47%). OSA patients with PH had significantly higher body-mass-index (BMI) (mean-difference (MD) = 3.432,P < 0.001), AHI (MD = 12.6,P < 0.001), ODI (standard-mean-difference (SMD) = 0.497), and T < 90% (SMD = 0.641), and lower meanSpO₂ (SMD = − 0.885) compared to those without PH. Age and sex were not different. Conclusions PH is relatively common among patients with OSA, with a pooled prevalence of approximately 29–31%. While OSA severity markers such as AHI and ODI were higher in PH patients, no consistent severity-dependent association with PH prevalence was observed.
- 30 October 2025
- Published by Wiley in The Laryngoscope
- Vol. 136 (4) , 1588-1600
General Versus Local Anesthesia in Stapes Surgery for Otosclerosis: Systematic Review and Meta‐Analysis
Objective: The aim of this study was to investigate the influence of type of anesthesia on audiometric results, surgery duration, quality‐of‐life and complications associated with stapes surgery in patients with otosclerosis. Data Sources: A comprehensive literature search was conducted in five databases, including PubMed, Embase, SCOPUS, WoS, and Google Scholar. Review Methods: We have identified studies comparing the outcomes of stapes surgery under local‐anesthesia (LA) versus general‐anesthesia (GA) and published up to 30 May 2025. All analyses were performed using Comprehensive‐Meta‐Analysis‐software and Review‐Manager. Results: Operating room occupancy was significantly lower in surgery under LA than GA ( MD = −17.27 min, 95% CI [−24.72, −9.83], p < 0.001, I 2 = 0%). Moreover, stapes surgery had a significantly shorter duration under LA compared to GA ( MD = −8.79, 95% CI [−15.69, −1.88], p = 0.01, I 2 = 0%). The meta‐analysis on changes in AC , BC , SR thresholds, and ABG showed no significant difference between patients who underwent LA or GA (AC: MD = 0.704, 95% CI [−3.344, 4.752], p = 0.733; BC : MD = 0.191, 95% CI [−2.231, 2.612], p = 0.877; SR : MD = 0.103, 95% CI [−3.621, 3.827], p = 0.957; ABG : MD = 0.451, 95% CI [−0.788, 1.689], p = 0.476). The meta‐analysis on ABG closure also showed no significant difference (< 10 dB : OR = 1.066, 95% CI [0.718, 1.582], p = 0.752; 10 to 20 dB : OR = 1.151, 95% CI [0.778, 1.705], p = 0.481; > 20 dB : OR = 0.833, 95% CI [0.537, 1.293], p = 0.416). Complications were the same for both types of anesthesia, but nausea and vomiting showed a marginally significant difference between LA and GA ( OR = 2.578, 95% CI [0.988, 6.732], p = 0.053, I 2 = 0%). Conclusion: Stapes surgery under LA is associated with shorter surgical and operating room times while demonstrating non‐inferior audiometric and safety outcomes compared to GA . These findings suggest that LA represents a safe and efficient alternative to GA for stapesplasty procedures. Level of Evidence: NA.
- 30 October 2025
- Published by Wiley in The Laryngoscope
- Vol. 136 (4) , 1588-1600
General Versus Local Anesthesia in Stapes Surgery for Otosclerosis: Systematic Review and Meta‐Analysis
Objective: The aim of this study was to investigate the influence of type of anesthesia on audiometric results, surgery duration, quality‐of‐life and complications associated with stapes surgery in patients with otosclerosis. Data Sources: A comprehensive literature search was conducted in five databases, including PubMed, Embase, SCOPUS, WoS, and Google Scholar. Review Methods: We have identified studies comparing the outcomes of stapes surgery under local‐anesthesia (LA) versus general‐anesthesia (GA) and published up to 30 May 2025. All analyses were performed using Comprehensive‐Meta‐Analysis‐software and Review‐Manager. Results: Operating room occupancy was significantly lower in surgery under LA than GA ( MD = −17.27 min, 95% CI [−24.72, −9.83], p < 0.001, I 2 = 0%). Moreover, stapes surgery had a significantly shorter duration under LA compared to GA ( MD = −8.79, 95% CI [−15.69, −1.88], p = 0.01, I 2 = 0%). The meta‐analysis on changes in AC , BC , SR thresholds, and ABG showed no significant difference between patients who underwent LA or GA (AC: MD = 0.704, 95% CI [−3.344, 4.752], p = 0.733; BC : MD = 0.191, 95% CI [−2.231, 2.612], p = 0.877; SR : MD = 0.103, 95% CI [−3.621, 3.827], p = 0.957; ABG : MD = 0.451, 95% CI [−0.788, 1.689], p = 0.476). The meta‐analysis on ABG closure also showed no significant difference (< 10 dB : OR = 1.066, 95% CI [0.718, 1.582], p = 0.752; 10 to 20 dB : OR = 1.151, 95% CI [0.778, 1.705], p = 0.481; > 20 dB : OR = 0.833, 95% CI [0.537, 1.293], p = 0.416). Complications were the same for both types of anesthesia, but nausea and vomiting showed a marginally significant difference between LA and GA ( OR = 2.578, 95% CI [0.988, 6.732], p = 0.053, I 2 = 0%). Conclusion: Stapes surgery under LA is associated with shorter surgical and operating room times while demonstrating non‐inferior audiometric and safety outcomes compared to GA . These findings suggest that LA represents a safe and efficient alternative to GA for stapesplasty procedures. Level of Evidence: NA.
- 8 March 2025
- Published by Springer Nature in Sleep and Breathing
- Vol. 29 (1) , 1-14
Sleep apnea in pulmonary hypertension patients: a systematic review and meta-analysis sleep disorders and pulmonary hypertension
Introduction Patients with pulmonary hypertension (PH) often have comorbid sleep apnea (SA), but the prevalence, severity, and clinical characteristics of PH patients with SA have not been well studied. Methods Using a combination of the keywords “pulmonary hypertension” and “sleep apnea,” the PubMed, Embase, Web of Science, and Scopus databases were searched for articles reporting the prevalence, severity, and clinical characteristics of PH patients with SA that were available through June 25, 2024. Results Of the 7969 studies, 39 were included in the final analysis. Prevalence of obstructive and central SA was 45.4% [39.2%, 51.6%]) and 9.3% [6%, 14.2%], respectively. The mean apnea hypopnea index (AHI) of patients with obstructive SA and PH was 18 [13.6, 22.4] with a standard error of 2.2. Subgroup analysis revealed that 51.4% [38.4%, 64.2%] had mild SA, 28% [22.5%, 33.6%] had moderate, and 20% [15.2%, 25%] had severe SA. PH patients with SA were characterized by male sex (odds ratio (OR) = 1.86 [1.45, 2.37], P < 0.001), older age (mean difference (MD) = -9.37 [-14.23, -4.43], P < 0.001), and higher body mass index (BMI) (MD = -2.16 [-3.32, -1.00], P < 0.001) compared to those without SA. However, mean pulmonary arterial pressure (mPAP) was not significantly different between SA and non-SA (MD = -2.4 [-5.1, 0.3], P = 0.078). Meta-regression showed no significant association between mPAP and AHI among patients with PH and SA (P = 0.13). Conclusion Our study found that SA is common in PH patients with certain clinical characteristics. We recommend conducting sleep studies in all PH patients, especially in older, overweight male patients.
- 8 March 2025
- Published by Springer Nature in Sleep and Breathing
- Vol. 29 (1) , 1-14
Sleep apnea in pulmonary hypertension patients: a systematic review and meta-analysis sleep disorders and pulmonary hypertension
Introduction Patients with pulmonary hypertension (PH) often have comorbid sleep apnea (SA), but the prevalence, severity, and clinical characteristics of PH patients with SA have not been well studied. Methods Using a combination of the keywords “pulmonary hypertension” and “sleep apnea,” the PubMed, Embase, Web of Science, and Scopus databases were searched for articles reporting the prevalence, severity, and clinical characteristics of PH patients with SA that were available through June 25, 2024. Results Of the 7969 studies, 39 were included in the final analysis. Prevalence of obstructive and central SA was 45.4% [39.2%, 51.6%]) and 9.3% [6%, 14.2%], respectively. The mean apnea hypopnea index (AHI) of patients with obstructive SA and PH was 18 [13.6, 22.4] with a standard error of 2.2. Subgroup analysis revealed that 51.4% [38.4%, 64.2%] had mild SA, 28% [22.5%, 33.6%] had moderate, and 20% [15.2%, 25%] had severe SA. PH patients with SA were characterized by male sex (odds ratio (OR) = 1.86 [1.45, 2.37], P < 0.001), older age (mean difference (MD) = -9.37 [-14.23, -4.43], P < 0.001), and higher body mass index (BMI) (MD = -2.16 [-3.32, -1.00], P < 0.001) compared to those without SA. However, mean pulmonary arterial pressure (mPAP) was not significantly different between SA and non-SA (MD = -2.4 [-5.1, 0.3], P = 0.078). Meta-regression showed no significant association between mPAP and AHI among patients with PH and SA (P = 0.13). Conclusion Our study found that SA is common in PH patients with certain clinical characteristics. We recommend conducting sleep studies in all PH patients, especially in older, overweight male patients.
- Open Access
- 1 January 2024
- Published by Wiley in Journal of Diabetes Research
- Vol. 2024 (1) , 3212795
Effects of Glucagon‐Like Peptide‐1 Receptor Agonists and Sodium‐Glucose Cotransporter 2 Inhibitors on Intima‐Media Thickness: Systematic Review and Meta‐Analysis
Background. Beyond glycemic control, glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and sodium‐glucose cotransporter 2 inhibitors (SGLT2is) have been proposed to reduce the risk of cardiovascular events. The aim of the present systematic review and meta‐analysis is to demonstrate the effects of GLP‐1 RA and SGLT2is on intima‐media thickness (IMT). Methods. PubMed, EMBASE, Web of Science, SCOPUS, and Google Scholar databases were searched from inception to September 9, 2023. All interventional and observational studies that provided data on the effects of GLP‐1 RAs or SGLT2is on IMT were included. Critical appraisal was performed using the Joanna Briggs Institute checklists. IMT changes (preintervention and postintervention) were pooled and meta‐analyzed using a random‐effects model. Subgroup analyses were based on type of medication (GLP‐1 RA: liraglutide and exenatide; SGLT2i: empagliflozin, ipragliflozin, tofogliflozin, and dapagliflozin), randomized clinical trials (RCTs), and diabetic patients. Results. The literature search yielded 708 related articles after duplicates were removed. Eighteen studies examined the effects of GLP‐1 RA, and eleven examined the effects of SGLT2i. GLP‐1 RA and SGLT2i significantly decreased IMT (MD = −0.123, 95% CI (‐0.170, ‐0.076), P < 0.0001, I2 = 98% and MD = −0.048, 95% CI (‐0.092, ‐0.004), P = 0.031, I2 = 95%, respectively). Metaregression showed that IMT change correlated with baseline IMT, whereas it did not correlate with gender, duration of diabetes, and duration of treatment. Conclusions. Treatment with GLP‐1 RA and SGLT2i can lower IMT in diabetic patients, and GLP‐1 RA may be more effective than SGLT2i.
- 1 January 2024
- Published by Wiley in Journal of Diabetes Research
- Vol. 2024 (1) , 3212795
Open AccessEffects of Glucagon‐Like Peptide‐1 Receptor Agonists and Sodium‐Glucose Cotransporter 2 Inhibitors on Intima‐Media Thickness: Systematic Review and Meta‐Analysis
Background. Beyond glycemic control, glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and sodium‐glucose cotransporter 2 inhibitors (SGLT2is) have been proposed to reduce the risk of cardiovascular events. The aim of the present systematic review and meta‐analysis is to demonstrate the effects of GLP‐1 RA and SGLT2is on intima‐media thickness (IMT). Methods. PubMed, EMBASE, Web of Science, SCOPUS, and Google Scholar databases were searched from inception to September 9, 2023. All interventional and observational studies that provided data on the effects of GLP‐1 RAs or SGLT2is on IMT were included. Critical appraisal was performed using the Joanna Briggs Institute checklists. IMT changes (preintervention and postintervention) were pooled and meta‐analyzed using a random‐effects model. Subgroup analyses were based on type of medication (GLP‐1 RA: liraglutide and exenatide; SGLT2i: empagliflozin, ipragliflozin, tofogliflozin, and dapagliflozin), randomized clinical trials (RCTs), and diabetic patients. Results. The literature search yielded 708 related articles after duplicates were removed. Eighteen studies examined the effects of GLP‐1 RA, and eleven examined the effects of SGLT2i. GLP‐1 RA and SGLT2i significantly decreased IMT (MD = −0.123, 95% CI (‐0.170, ‐0.076), P < 0.0001, I2 = 98% and MD = −0.048, 95% CI (‐0.092, ‐0.004), P = 0.031, I2 = 95%, respectively). Metaregression showed that IMT change correlated with baseline IMT, whereas it did not correlate with gender, duration of diabetes, and duration of treatment. Conclusions. Treatment with GLP‐1 RA and SGLT2i can lower IMT in diabetic patients, and GLP‐1 RA may be more effective than SGLT2i.
- Open Access
- 25 May 2022
- Published by Taylor & Francis in International Journal of Mental Health
- Vol. 51 (3) , 286-290
Mass management of mental health issues during COVID-19 pandemic: the role of professional volunteer groups; an Iranian experience
Several reports, including the studies published in recent issues of the International Journal of Mental Health, have shown the impact of the COVID-19 pandemic on mental health among the general po...
- 25 May 2022
- Published by Taylor & Francis in International Journal of Mental Health
- Vol. 51 (3) , 286-290
Open AccessMass management of mental health issues during COVID-19 pandemic: the role of professional volunteer groups; an Iranian experience
Several reports, including the studies published in recent issues of the International Journal of Mental Health, have shown the impact of the COVID-19 pandemic on mental health among the general po...
- Open Access
- 19 November 2021
- Published by Royal College of Psychiatrists in BJPsych International
- Vol. 19 (3) , 58-62
Tramadol, captagon and khat use in the Eastern Mediterranean Region: opening Pandora's box
As defined by the World Health Organization, the Eastern Mediterranean Region (EMR), given its special geopolitical situation and internal/external conflicts, faces an increase in illegal activities such as drug production and trafficking, highlighting the need for a comprehensive understanding of the substance use situation. On the basis of a review of published papers between 2015 and 2021 we briefly review substance use in the EMR with special focus on the emerging drugs pertinent to this region, namely tramadol, captagon and khat.
- 19 November 2021
- Published by Royal College of Psychiatrists in BJPsych International
- Vol. 19 (3) , 58-62
Open AccessTramadol, captagon and khat use in the Eastern Mediterranean Region: opening Pandora's box
As defined by the World Health Organization, the Eastern Mediterranean Region (EMR), given its special geopolitical situation and internal/external conflicts, faces an increase in illegal activities such as drug production and trafficking, highlighting the need for a comprehensive understanding of the substance use situation. On the basis of a review of published papers between 2015 and 2021 we briefly review substance use in the EMR with special focus on the emerging drugs pertinent to this region, namely tramadol, captagon and khat.
- 25 October 2021
- Published by Taylor & Francis in Expert Review of Anti-infective Therapy
- Vol. 20 (4) , 585-609
Comparative effectiveness of pharmacological interventions on mortality and the average length of hospital stay of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials
Up to now, numerous randomized controlled trials (RCTs) have examined various drugs as possible treatments for Coronavirus Disease 2019 (COVID-19), but the results were diverse and occasionally even inconsistent with each other. To this point, decisive consensus on treatment is requiring. Therefore, we performed a systematic review and meta-analysis (SR-MAs) to assess the comparative effectiveness of pharmacological agents in published RCTs. A literature search was performed using PubMed, SCOPUS, EMBASE, and Web of Science databases. RCTs evaluating mortality and the average length of hospital stay to standard of care (SOC)/placebo/control were included in our meta-analysis. RCTs mainly were classified into five categories of drugs, including anti-inflammatory, antiviral, antiparasitic, antibody and antibiotics. Meta-analysis was done on 5 drugs classes and sub-group meta-analysis was done on single drugs and moderate or severe stage of disease. : Mortality and the average length of hospital stay of COVID-19 patients was significantly reduced with anti-inflammatory drugs (odds ratio [OR]: 0.77, 95% confidence interval [CI]: 0.69 to 0.85, P<0.00001, and mean difference [MD]: -1.41, CI:-1.75 to -1.07, P<0.00001, respectively) compared to SOC/control/placebo. Furthermore, antiparasitic was associated with reduced length of hospital stay (MD: -0.65, CI: -1.26 to -0.03, P<0.05) in comparison to SOC/placebo/control. However, no difference was found in other pharmacological interventions in comparison to SOC/placebo/control in outcomes.
- 25 October 2021
- Published by Taylor & Francis in Expert Review of Anti-infective Therapy
- Vol. 20 (4) , 585-609
Comparative effectiveness of pharmacological interventions on mortality and the average length of hospital stay of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials
Up to now, numerous randomized controlled trials (RCTs) have examined various drugs as possible treatments for Coronavirus Disease 2019 (COVID-19), but the results were diverse and occasionally even inconsistent with each other. To this point, decisive consensus on treatment is requiring. Therefore, we performed a systematic review and meta-analysis (SR-MAs) to assess the comparative effectiveness of pharmacological agents in published RCTs. A literature search was performed using PubMed, SCOPUS, EMBASE, and Web of Science databases. RCTs evaluating mortality and the average length of hospital stay to standard of care (SOC)/placebo/control were included in our meta-analysis. RCTs mainly were classified into five categories of drugs, including anti-inflammatory, antiviral, antiparasitic, antibody and antibiotics. Meta-analysis was done on 5 drugs classes and sub-group meta-analysis was done on single drugs and moderate or severe stage of disease. : Mortality and the average length of hospital stay of COVID-19 patients was significantly reduced with anti-inflammatory drugs (odds ratio [OR]: 0.77, 95% confidence interval [CI]: 0.69 to 0.85, P<0.00001, and mean difference [MD]: -1.41, CI:-1.75 to -1.07, P<0.00001, respectively) compared to SOC/control/placebo. Furthermore, antiparasitic was associated with reduced length of hospital stay (MD: -0.65, CI: -1.26 to -0.03, P<0.05) in comparison to SOC/placebo/control. However, no difference was found in other pharmacological interventions in comparison to SOC/placebo/control in outcomes.